MindBio Therapeutics Corp. has recently started recruiting participants for an innovative clinical trial that combines LSD microdosing with Meaning Centred Psychotherapy to help cancer patients experiencing emotional distress. This groundbreaking trial aims to address the mental health needs of advanced stage cancer patients, making it the first of its kind in the world.
The Phase 2 trial will involve a total of 40 participants who have stage IV solid tumor cancer and are also experiencing emotional distress. These patients will be randomly assigned to receive microdoses of LSD along with Meaning Centred Psychotherapy, which is a well-established psychotherapeutic intervention for cancer patients dealing with symptoms of anxiety and depression.
Justin Hanka, the CEO of MindBio Therapeutics, believes that this research has the potential to revolutionize the treatment of mental health issues in cancer patients. End-of-life distress can have devastating effects on both patients and their families, and psychedelics have shown promise in transforming psychological states.